36 results about "Pregnancy outcomes" patented technology

The presently disclosed subject matter provides methods of diagnosis of cancer or adverse pregnancy outcomes in a subject by measuring amounts of one or more microRNAs present in cancer-derived exosomes isolated from a biological sample from the subject.

The invention provides serum-based, diagnostic, biological assays for predicting disorders of pregnancy resulting from poor trophoblast and / or placental ischemia, including preeclampsia. Serum samples from such subjects exhibit an ability to disrupt the architecture involving fetal trophoblasts and maternal endothelial cells in a three-dimensional, dual cell co-culture system provided herein, in contrast to normal pregnancy serum samples. Based on these distinctions, the assays are employed to predict pregnancy outcomes as early as first trimester.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy and a method of treatment to facilitate same.Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes and the identification of therapeutic targets. Taught herein is a composition comprising reagents required for prognostic evaluation and treatment. The present disclosure teaches an assay to determine the risk that a pregnant woman may undergo a miscarriage. Biomarkers used in the assays include CSF3, CSF3R, IL-17A or P1GF.

The invention discloses a serum / blood plasma polypeptide marker related to gestational diabetes mellitus auxiliary early diagnosis and application thereof. The serum / blood plasma polypeptide marker ischaracterized in that the marker is selected from arbitrary one or more polypeptides of Q6PFW1, P35658, P32004 and Q9Y4H2. The serum / blood plasma polypeptide marker serving as a detection target is applied to preparation of gestational diabetes mellitus auxiliary early diagnosis reagents. The expression quantity of the marker for detecting pregnancy serum / blood plasma can be used in GDM auxiliaryearly diagnosis. Support is provided to clinical doctors for accurately predicting the GDM pathogenesis outcome of pregnancy and timely adopting personal prevention and treatment schemes, so that theoccurrence rate of GDM can be furthest reduced, and adverse pregnancy outcomes can be reduced.

The invention discloses a female vaginal dominant bacterium Lactobacillus gasseri (Lactobacillus gasseri) H87 and its application in the preparation of medicines for preventing premature birth, belonging to the technical field of medical microorganisms. The L. gasseri H87 is a new genus of Lactobacillus gasseri isolated from the human body and has no repelling effect. The specific L. gasseri H87 antimicrobial peptide gassericin maintains the balance of the vaginal flora and has a higher resistance to The ability of vaginal epithelial cells to adhere reduces the risk of inflammation in the genitourinary region of patients, and at the same time reduces the risk of complications during pregnancy for pregnant women, and the strain can be stored for a long time to facilitate production. The lack of Lactobacillus gasseri may have adverse pregnancy outcomes for pregnant women, such as premature birth, and reshape the vaginal microenvironment of women. Therefore, this strain can better meet the actual clinical application needs and provide new ideas for reducing the premature birth rate. .

The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function.The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester.The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and / or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.